MedVellum
MedVellum
Back to Library
Endocrinology
Oncology
Nephrology
Emergency Medicine
EMERGENCY

Hypercalcaemia

High EvidenceUpdated: 2025-12-24

On This Page

Red Flags

  • Severe hypercalcaemia (calcium greater than 3.5 mmol/L)
  • Altered consciousness or confusion
  • Cardiac arrhythmia (short QT, bradycardia)
  • Severe dehydration
  • Suspected underlying malignancy
Overview

Hypercalcaemia

1. Clinical Overview

Summary

Hypercalcaemia is defined as serum calcium greater than 2.6 mmol/L (adjusted for albumin). It is a common metabolic abnormality with potentially life-threatening consequences if severe (greater than 3.5 mmol/L). Primary hyperparathyroidism and malignancy account for over 90% of cases. Symptoms classically remembered as "bones, stones, groans, and moans." Treatment of severe hypercalcaemia is an emergency requiring aggressive IV fluid resuscitation followed by bisphosphonates. [1,2]

Key Facts

  • Definition: Adjusted calcium greater than 2.6 mmol/L (check albumin correction).
  • Severe: Greater than 3.5 mmol/L (medical emergency).
  • Two Main Causes: Primary hyperparathyroidism (90% outpatient), Malignancy (70% inpatient). [3]
  • Key Discriminator: PTH level - elevated or inappropriately normal in hyperparathyroidism; suppressed in malignancy.
  • Classic Symptoms: "Bones, stones, groans, and moans" + polyuria.
  • Acute Treatment: IV saline rehydration → bisphosphonates.

Clinical Pearls

The 90-90 Rule: Primary hyperparathyroidism (PHPT) + malignancy cause 90% of hypercalcaemia. In the community, 90% is PHPT. In hospital, malignancy predominates.

Check the PTH First: PTH is the key discriminating test. High/inappropriate normal = PTH-mediated (PHPT, FHH, lithium). Suppressed = non-PTH mediated (malignancy, granulomatous disease, vitamin D toxicity).

Malignancy-Related Hypercalcaemia is a Poor Prognostic Sign: Median survival is 30 days after diagnosis of hypercalcaemia of malignancy. Consider goals of care discussion.

Short QT on ECG: Hypercalcaemia shortens the QT interval (opposite of hypocalcaemia). May cause arrhythmias.


2. Epidemiology

Incidence and Demographics

  • Overall Prevalence: 1-2% of general population.
  • Primary Hyperparathyroidism: 1-3 per 1,000; increases with age.
  • Malignancy-Associated: 10-30% of cancer patients at some point.
  • Sex: PHPT more common in women (3:1); HHM more equal.
  • Age: PHPT peaks post-menopause; malignancy varies by cancer type.

Causes of Hypercalcaemia

PTH-Mediated (PTH Elevated or Inappropriately Normal)

CauseNotes
Primary HyperparathyroidismSingle adenoma (85%), Hyperplasia (15%), Carcinoma (less than 1%)
Tertiary HyperparathyroidismAfter prolonged secondary (CKD); autonomous PTH secretion
Familial Hypocalciuric Hypercalcaemia (FHH)CaSR mutation; benign; low urinary calcium excretion
Lithium TherapyShifts PTH set-point; reversible
MEN SyndromesMEN1, MEN2A include hyperparathyroidism

Non-PTH Mediated (PTH Suppressed)

CauseMechanism
MalignancyBone metastases (breast, lung, prostate, myeloma); PTHrP secretion (squamous cancers); 1,25-Vit D production (lymphoma)
Granulomatous DiseaseSarcoidosis, TB → macrophage 1-alpha hydroxylase → ↑1,25(OH)2D
Vitamin D IntoxicationExcess supplementation or dermal production
Milk-Alkali SyndromeExcessive calcium carbonate + alkali intake
ThyrotoxicosisIncreased bone turnover
ImmobilisationParticularly in Paget's, young patients
DrugsThiazides, Vitamin A toxicity

3. Pathophysiology

Step 1: Normal Calcium Homeostasis

  • Normal Range: 2.2-2.6 mmol/L (adjusted).
  • Key Regulators: PTH, Vitamin D, Calcitonin (minor role).
  • PTH: ↑Bone resorption, ↑Renal calcium reabsorption, ↑1,25-Vit D synthesis.
  • Vitamin D: ↑Intestinal calcium absorption, ↑Bone resorption.

Step 2: Mechanisms of Hypercalcaemia

Primary Hyperparathyroidism

  • Autonomous PTH secretion (adenoma usually).
  • Loss of normal feedback inhibition.
  • Increased bone resorption + renal calcium reabsorption + 1,25-Vit D.

Hypercalcaemia of Malignancy Three main mechanisms:

  1. Humoral Hypercalcaemia (HHM): Tumour secretes PTHrP → mimics PTH actions. Common in squamous cell carcinomas.
  2. Osteolytic Metastases: Direct bone destruction by tumour → calcium release. Common in breast, lung, prostate, myeloma.
  3. Calcitriol Production: Lymphomas produce 1,25(OH)2D → ↑intestinal calcium absorption.

Granulomatous Disease

  • Activated macrophages express 1-alpha hydroxylase.
  • Unregulated conversion of 25-OH-D to 1,25(OH)2D.
  • Increased intestinal calcium absorption.

Step 3: Systemic Effects

           HYPERCALCAEMIA
                 ↓
    ┌────────────┼────────────┐
    ↓            ↓            ↓
NEUROLOGICAL  RENAL      CARDIOVASCULAR
    ↓            ↓            ↓
Confusion    Polyuria     Short QT
Lethargy     Nephrogenic  Bradycardia
Coma         DI           Arrhythmias
             Stones       HTN
             AKI

Step 4: Organ-Specific Effects

SystemMechanismClinical Effect
RenalADH resistance (nephrogenic DI)Polyuria, polydipsia, dehydration
NervousNeuronal membrane stabilisationConfusion, lethargy, coma
CardiacCalcium influx effectsShort QT, bradycardia, arrhythmias
GISmooth muscle dysfunctionConstipation, nausea, anorexia, pancreatitis
SkeletalBone resorptionOsteoporosis, fractures (PHPT)

4. Clinical Presentation

Classic Mnemonic: "Bones, Stones, Groans, and Moans"

Additional Features

Symptoms by Severity

SeverityCalcium LevelSymptoms
Mild2.6-3.0 mmol/LOften asymptomatic or vague fatigue
Moderate3.0-3.5 mmol/LPolyuria, constipation, nausea, mild confusion
SevereGreater than 3.5 mmol/LSevere confusion, cardiac arrhythmias, coma, can be fatal

Red Flags - "The Don't Miss" Signs

  1. Calcium greater than 3.5 mmol/L → Emergency; aggressive treatment.
  2. Altered consciousness → May indicate severe hypercalcaemia or CNS metastases.
  3. Cardiac symptoms/ECG changes → Short QT, arrhythmias.
  4. Suspected malignancy → Weight loss, new mass, bone pain.
  5. Hypercalcaemic crisis → AKI, dehydration, cardiac arrhythmias.

Bones
Bone pain, osteoporosis, fractures.
Stones
Renal calculi (calcium oxalate/phosphate).
Groans
GI symptoms (constipation, nausea, abdominal pain, pancreatitis).
Moans
Neuropsychiatric (confusion, depression, lethargy, coma).
5. Clinical Examination

General Assessment

  • Hydration status (dry mucous membranes, reduced skin turgor).
  • Conscious level (confusion, drowsiness).
  • Vital signs (BP, pulse - bradycardia).

Focused Examination

Head and Neck

  • Goitre or thyroid nodule (thyrotoxicosis, parathyroid pathology).
  • Cervical lymphadenopathy (malignancy, sarcoidosis).
  • Band keratopathy (chronic hypercalcaemia - rare).

Chest

  • Lung examination (consolidation, effusion - malignancy).
  • Breast examination if appropriate.

Abdomen

  • Abdominal masses (renal, hepatic).
  • Renal angle tenderness (stones).

Skeletal

  • Bone tenderness (metastases, myeloma).
  • Kyphosis, height loss (osteoporosis).

Neurological

  • Muscle weakness (proximal myopathy).
  • Hypo/hyperreflexia (variable).
  • Mental state assessment.

Clues to Underlying Cause

FindingSuggests
Enlarged parathyroids (rarely palpable)PHPT
Lymphadenopathy, organomegalySarcoidosis, lymphoma
Bony tenderness, fracturesMyeloma, metastases
CachexiaMalignancy
Skin lesionsSarcoidosis (lupus pernio)

6. Investigations

First-Line Investigations

Biochemistry

TestPurposeInterpretation
Serum Calcium (adjusted)Confirm hypercalcaemiaAdjust for albumin
AlbuminCalcium correctionAdjusted Ca = measured Ca + 0.02 × (40 - albumin)
PTH (Parathyroid Hormone)KEY discriminating testHigh/normal = PHPT; Low/suppressed = malignancy
PhosphateTypically low in PHPTLow in PHPT; may be high in granulomatous
ALPBone turnoverElevated in bone mets, Paget's
U&E/CreatinineRenal functionAKI from dehydration
MagnesiumCo-existing abnormalityMay be low

Calcium Correction Formula Adjusted Calcium = Measured Calcium + 0.02 × (40 - Albumin)

Second-Line (Based on PTH Result)

If PTH Elevated or Inappropriately Normal:

TestPurpose
24-hour urine calcium/creatinineDifferentiates PHPT from FHH (FHH has low urinary calcium clearance ratio less than 0.01)
PTH againConfirm if borderline
Parathyroid ImagingSestamibi scan, neck USS, 4D-CT (if surgery planned)
DEXA scanAssess bone density
Genetic testingIf FHH suspected or MEN

If PTH Suppressed:

TestPurpose
PTHrPHumoral hypercalcaemia of malignancy
Vitamin D metabolites25-OH-D (intoxication), 1,25(OH)2D (granulomatous, lymphoma)
Serum/Urine protein electrophoresisMyeloma screen
Chest X-rayMalignancy, sarcoidosis
CT TAPStaging if malignancy suspected
ACE levelSarcoidosis

ECG

  • Short QT interval: Characteristic finding.
  • Bradycardia, AV block (severe).
  • Arrhythmias.

7. Management

Management Algorithm

           CONFIRMED HYPERCALCAEMIA
           (Adjusted calcium greater than 2.6 mmol/L)
                        ↓
┌─────────────────────────────────────────────┐
│              ASSESS SEVERITY                │
│  Mild: 2.6-3.0   Moderate: 3.0-3.5          │
│  Severe: greater than 3.5 mmol/L            │
└─────────────────────────────────────────────┘
                        ↓
            ┌───────────┴───────────┐
            ↓                       ↓
      MILD/MODERATE             SEVERE
      (Asymptomatic)        (or Symptomatic)
            ↓                       ↓
    Investigate cause       EMERGENCY
    Outpatient if stable    TREATMENT
                                ↓
┌─────────────────────────────────────────────┐
│  1. IV SALINE (aggressive rehydration)      │
│     3-6L in first 24 hours                  │
│  2. IV BISPHOSPHONATE                       │
│     Zoledronate 4mg OR Pamidronate 60-90mg  │
│  3. Treat underlying cause                  │
│  4. Consider: Steroids, Calcitonin,         │
│     Denosumab, Dialysis                     │
└─────────────────────────────────────────────┘

Acute Treatment of Severe Hypercalcaemia

Step 1: IV Fluid Resuscitation

  • 0.9% Normal Saline: 3-6 litres in first 24 hours.
  • Mechanism: Expands volume; increases renal calcium excretion.
  • Monitor: Fluid balance, urine output (target greater than 200mL/hr).
  • Caution: Cardiac failure risk in elderly.

Step 2: IV Bisphosphonate

  • Zoledronate 4mg IV (preferred) or Pamidronate 60-90mg IV.
  • Mechanism: Inhibits osteoclast-mediated bone resorption.
  • Onset: 2-4 days for effect.
  • Precaution: Avoid if eGFR less than 30 (renal injury risk).

Step 3: Additional Therapies (If Needed)

TherapyIndicationMechanism
Calcitonin (SC/IM)Bridge while awaiting bisphosphonateRapid but transient effect (tachyphylaxis after 48h)
CorticosteroidsSarcoidosis, lymphoma, myeloma, Vit D toxicityReduces 1,25-Vit D production
DenosumabRefractory or bisphosphonate contraindicatedRANKL inhibitor; potent
DialysisRenal failure, refractory hypercalcaemiaRemoves calcium directly

Specific Treatments by Cause

Primary Hyperparathyroidism

  • Mild asymptomatic: Monitor or surgery if meeting criteria.
  • Symptomatic/severe: Surgery (parathyroidectomy) is curative.
  • Cinacalcet: Calcimimetic for those unsuitable for surgery.

Malignancy

  • Treat underlying cancer.
  • Bisphosphonates/denosumab for ongoing management.
  • Palliative care discussion if prognosis poor.

Granulomatous Disease

  • Corticosteroids (effective).
  • Avoid sun exposure, vitamin D supplements.

Vitamin D Toxicity

  • Stop vitamin D supplements.
  • Steroids if needed.
  • Hydration.

What NOT to Do

  • Avoid thiazide diuretics: Increase calcium reabsorption.
  • DO NOT use loop diuretics routinely: Only if fluid overload.
  • Do not delay investigation: PTH is key.

8. Complications

Acute Complications

ComplicationFeaturesManagement
Hypercalcaemic crisisSevere dehydration, AKI, comaAggressive IV fluids, ICU
Cardiac arrhythmiasShort QT, bradycardia, arrestCardiac monitoring, treat calcium
Acute kidney injuryVasoconstriction, dehydrationIV fluids; avoid nephrotoxins
PancreatitisAbdominal pain, raised amylaseSupportive care

Chronic Complications

ComplicationCause
NephrolithiasisHypercalciuria → calcium stones
NephrocalcinosisCalcium deposition in renal parenchyma
Chronic kidney diseaseChronic nephrocalcinosis
OsteoporosisIncreased bone resorption (PHPT)
Peptic ulcer diseaseIncreased gastrin secretion

Complications of Treatment

TreatmentComplication
BisphosphonatesOsteonecrosis of jaw (rare), renal injury, hypocalcaemia
DenosumabHypocalcaemia, osteonecrosis of jaw
SurgeryHypocalcaemia (hungry bone syndrome), recurrent laryngeal nerve injury

9. Prognosis and Outcomes

Prognosis by Cause

CausePrognosis
Primary HyperparathyroidismExcellent with surgery; cure rate greater than 95%
Hypercalcaemia of MalignancyPoor; median survival 30 days; reflects advanced disease
Granulomatous DiseaseGood with treatment
Vitamin D ToxicityExcellent if identified and stopped

Hypercalcaemia of Malignancy

  • Indicates advanced or disseminated disease.
  • Median survival approximately 30 days from diagnosis.
  • Important to discuss prognosis and goals of care.

Monitoring

  • Recheck calcium within 24-48 hours of treatment.
  • Long-term monitoring for PHPT if conservative management.
  • Follow-up for underlying malignancy.

10. Evidence and Guidelines

Key Guidelines

GuidelineOrganisationKey Recommendations
Society for Endocrinology Emergency GuidanceUKIV saline + bisphosphonates for severe
Fourth International Workshop on PHPTInternationalSurgical criteria for asymptomatic PHPT
ASCO GuidelinesUSAManagement of hypercalcaemia of malignancy

Landmark Studies

1. Bilezikian et al. PHPT Guidelines (2014) [5]

  • Question: When to operate on asymptomatic PHPT?
  • Criteria: Calcium greater than 0.25 mmol/L above normal; age less than 50; T-score less than -2.5; eGFR less than 60; nephrolithiasis.
  • Impact: Standardised surgical indications.
  • PMID: 25078146.

2. Major et al. Zoledronate vs Pamidronate (2001) [6]

  • Question: Zoledronate vs pamidronate for hypercalcaemia of malignancy?
  • N: 287 patients.
  • Result: Zoledronate superior response rate and duration.
  • Impact: Zoledronate became preferred bisphosphonate.
  • PMID: 11304472.

3. Hu et al. Denosumab (2014)

  • Question: Denosumab for bisphosphonate-refractory hypercalcaemia?
  • Result: Effective in reducing calcium in refractory cases.
  • Impact: Alternative for bisphosphonate failure.
  • PMID: 24446653.

11. Patient and Layperson Explanation

What is Hypercalcaemia?

Hypercalcaemia means there is too much calcium in your blood. Calcium is important for bones, nerves, and muscles, but too much can cause problems.

What Causes It?

The two most common causes are:

  1. Overactive parathyroid glands (small glands in the neck that control calcium).
  2. Cancer – some cancers can raise calcium levels.

Other causes include excessive vitamin D, certain medications, and some inflammatory conditions.

What Are the Symptoms?

Mild hypercalcaemia may have no symptoms. Higher levels can cause:

  • Tiredness and weakness.
  • Excessive thirst and urinating a lot.
  • Nausea, loss of appetite, constipation.
  • Confusion or difficulty thinking clearly.
  • Bone pain.
  • Kidney stones.

Doctors remember these as: "Bones, stones, groans, and moans."

How is it Diagnosed?

  • Blood tests to check calcium levels and parathyroid hormone (PTH).
  • Sometimes further tests including scans if a cause like cancer is suspected.

How is it Treated?

  • Fluids: Through a drip (IV) to flush out excess calcium.
  • Medications: Bisphosphonates (e.g., zoledronate) to reduce calcium.
  • Treating the cause: Surgery for parathyroid adenoma; cancer treatment if that's the cause.

When to Seek Help

  • Severe confusion or drowsiness.
  • Persistent vomiting or not able to drink.
  • Palpitations or chest discomfort.
  • Severe bone pain.

What is the Outlook?

  • If caused by overactive parathyroid glands, surgery is usually very successful.
  • If caused by cancer, treatment focuses on controlling calcium levels and managing the underlying disease.

12. References

Primary Sources

  1. Ahmad S, et al. Hypercalcaemia: an evidence-based approach to clinical cases. Clin Med (Lond). 2016;16:277-281. PMID: 27251920.
  2. Minisola S, et al. The diagnosis and management of hypercalcaemia. BMJ. 2015;350:h2723. PMID: 26037642.
  3. Stewart AF. Hypercalcemia associated with cancer. N Engl J Med. 2005;352:373-379. PMID: 15673803.
  4. Society for Endocrinology. Acute hypercalcaemia emergency guidance. https://www.endocrinology.org/clinical-practice/clinical-guidance/. Accessed 2025.
  5. Bilezikian JP, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99:3561-3569. PMID: 25078146.
  6. Major P, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy. J Clin Oncol. 2001;19:558-567. PMID: 11208851.

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists.

Last updated: 2025-12-24

At a Glance

EvidenceHigh
Last Updated2025-12-24
Emergency Protocol

Red Flags

  • Severe hypercalcaemia (calcium greater than 3.5 mmol/L)
  • Altered consciousness or confusion
  • Cardiac arrhythmia (short QT, bradycardia)
  • Severe dehydration
  • Suspected underlying malignancy

Clinical Pearls

  • **The 90-90 Rule**: Primary hyperparathyroidism (PHPT) + malignancy cause 90% of hypercalcaemia. In the community, 90% is PHPT. In hospital, malignancy predominates.
  • **Malignancy-Related Hypercalcaemia is a Poor Prognostic Sign**: Median survival is 30 days after diagnosis of hypercalcaemia of malignancy. Consider goals of care discussion.
  • **Short QT on ECG**: Hypercalcaemia shortens the QT interval (opposite of hypocalcaemia). May cause arrhythmias.

Guidelines

  • NICE Guidelines
  • BTS Guidelines
  • RCUK Guidelines